Andrew Wesley Stacey, MD

Andrew Wesley Stacey, MD


On staff since October 2016

  • Dr. Andrew Stacey grew up in northeast Ohio. He earned a bachelor’s degree and master's degree in Statistics at the Brigham Young University where he was also a linebacker on the football team. During college he took two years off school and athletics to volunteer for his church in Northern Italy. He completed his medical degree at the Ohio State University and completed his ophthalmology training at the University of Michigan Kellogg Eye Center. He completed a fellowship in ocular oncology at Moorfields Eye Hospital in London, U.K.

  • Other Publications

    • Stacey AW, Pulido JS
      The Concept of Minimal Residual Disease in the Treatment and Staging of Vitreoretinal Lymphoma.
      32404846 Retina (Philadelphia, Pa.), 2020 July : 40(7)1213-1214
    • Lee HJ Jr, Stacey A, Klesert TR, Wells C, Skalet AH, Bloch C, Fung A, Bowen SR, Wong TP, Shibata D, Halasz LM, Rengan R
      Corneal Substructure Dosimetry Predicts Corneal Toxicity in Patients With Uveal Melanoma Treated With Proton Beam Therapy.
      30763658 International journal of radiation oncology, biology, physics, 2019 Jun 1 : 104(2)374-382
    • Stacey AW, Pefkianaki M, Ilginis T, Michaelides M, Hykin P, Webster A, Moore AT, Sagoo MS
      Clinical Features and Multi-Modality Imaging of Isolated Retinal Astrocytic Hamartoma.
      30768223 Ophthalmic surgery, lasers & imaging retina, 2019 Feb 1 : 50(2)e1-e9
    • Stacey AW, Clarke B, Moraitis C, Fabian ID, Smith V, Sagoo MS, Reddy MA
      The Incidence of Binocular Visual Impairment and Blindness in Children with Bilateral Retinoblastoma.
      30675470 Ocular oncology and pathology, 2019 Jan. : 5(1)1-7 PMCID:PMC6341332
    • Fabian ID, Stacey AW, Harby LA, Arora AK, Sagoo MS, Cohen VML
      Primary photodynamic therapy with verteporfin for pigmented posterior pole cT1a choroidal melanoma: a 3-year retrospective analysis.
      29439995 The British journal of ophthalmology, 2018 Dec. : 102(12)1705-1710
    • Fabian ID, Stacey AW, Naeem Z, Onadim Z, Chowdhury T, Duncan C, Sagoo MS, Reddy MA
      Strabismus in retinoblastoma survivors with long-term follow-up.
      30009948 Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus, 2018 Aug. : 22(4)276.e1-276.e7
    • Gillette TB, Cabrera MT, Tarlock K, Murphy CE, Chisholm KM, Stacey AW
      Rapidly Progressive, Isolated Subretinal Leukemic Relapse: A Case Report.
      30643765 Ocular oncology and pathology, 2018 June : 4(4)220-224 PMCID:PMC6322080
    • Fabian ID, Stacey AW, Johnson KC, Chowdhury T, Duncan C, Reddy MA, Sagoo MS
      Primary enucleation for group D retinoblastoma in the era of systemic and targeted chemotherapy: the price of retaining an eye.
      28659391 The British journal of ophthalmology, 2018 Feb. : 102(2)265-271
    • Fabian ID, Thaung C, AlHarby L, Sisley K, Mudhar HS, Doherty RE, Stacey AW, Arora AK, Cohen VML, Sagoo MS
      Late Solitary Extraocular Recurrence From Previously Resected Iris Melanoma.
      28673748 American journal of ophthalmology, 2017 Sept. : 18197-105
    • Stacey AW, Lavric A, Thaung C, Siddiq S, Sagoo MS
      Solitary Iris Plasmacytoma With Anterior Chamber Crystalline Deposits.
      28594699 Cornea, 2017 July : 36(7)875-877
    • Fabian ID, Naeem Z, Stacey AW, Chowdhury T, Duncan C, Reddy MA, Sagoo MS
      Long-term Visual Acuity, Strabismus, and Nystagmus Outcomes Following Multimodality Treatment in Group D Retinoblastoma Eyes.
      28501391 American journal of ophthalmology, 2017 July : 179137-144
    • Fabian ID, Stacey AW, Chowdhury T, Duncan C, Karaa EK, Scheimberg I, Reddy MA, Sagoo MS
      High-Risk Histopathology Features in Primary and Secondary Enucleated International Intraocular Retinoblastoma Classification Group D Eyes.
      28302322 Ophthalmology, 2017 June : 124(6)851-858
    • Fabian ID, Stacey AW, Johnson KP, Onadim Z, Chowdhury T, Duncan C, Reddy MA, Sagoo MS
      Primary intravenous chemotherapy for group D retinoblastoma: a 13-year retrospective analysis.
      27965263 The British journal of ophthalmology, 2017 Jan. : 101(1)82-88
    • Stacey A, Sheffield NC, Crandall KA
      Calculating expected DNA remnants from ancient founding events in human population genetics.
      18928554 BMC genetics, 2008 Oct 17 : 966 PMCID:PMC2588638
    • Sa G, Hitomi M, Harwalkar J, Stacey AW, GC GC, Stacey DW
      Ras is active throughout the cell cycle, but is able to induce cyclin D1 only during G2 phase.
      12429909 Cell cycle (Georgetown, Tex.), 2002 Jan. : 1(1)50-8


Board Certification(s)


Medical/Professional School

Brigham Young University at Provo, Provo, UT
Ohio State University College of Medicine, Columbus, OH


University of Michigan W.K. Kellogg Eye Center, Ann Arbor, MI


Moorfields Eye Hospital, London, England

Clinical Interests

Dr. Stacey specializes in the diagnosis and treatment of eye cancer and other growths in and around the eyes. He treats children with retinoblastoma, Coats' disease, medulloepithelioma, retinal vascular tumors, melanoma, and many other growths and tumors in the eyes. 

Research Description

Dr. Stacey's research is dedicated to improving the treatment options for children and families with retinoblastoma both in the USA and in lower-income countries around the world.